Potential Role of Selective Serotonin Reuptake Inhibitors in Improving Functional Outcome after Stroke
The great advances in acute stroke treatment during the last decades have changed life after stroke considerably. However, the use of intravenous thrombolysis and endovascular thrombectomy is limited by a relatively narrow time window or contraindications for treatment. Further, patients receiving acute reperfusion therapies may still have cognitive and emotional complications due to underlying brain infarcts even though physical problems may almost disappear. Consequently, stroke is still a frequent cause of adult disability and death worldwide, and an effort to identify additional treatments to enhance recovery, preferably also feasible in the time after the acute phase, is warranted. Albeit several drugs and treatment modalities have been studied for their potential to enhance recovery after stroke, no treatment has unambiguously proven to potentiate the rehabilitation process. A promising candidate for pharmacological treatment is selective serotonin reuptake inhibitors (SSRIs), a group of commonly used antidepressants that may also possess neuro-regenerative properties. The current paper reviews the evidence for SSRIs as potential enhancers of stroke recovery and discusses the potential mechanisms behind the effects reported and the implications for the management of patients post-stoke, including potential adverse events and drug–drug interactions.
Compliance with Ethical Standards
Conflict of Interest
Janne Kaergaard Mortensen and Grethe Andersen have no conflicts of interest.
No funding was received to assist with the preparation of this review.
- 4.Berger M, Gray JA, Roth BL. The expanded biology of serotonin. Annu Rev Med. 2009;60:355–66. https://doi.org/10.1146/annurev.med.60.042307.110802.CrossRefPubMedPubMedCentralGoogle Scholar
- 11.He YT, Tang BS, Cai ZL, Zeng SL, Jiang X, Guo Y. Effects of fluoxetine on neural functional prognosis after ischemic stroke: a randomized controlled study in china. J Stroke Cerebrovasc Dis. 2016;25(4):761–70. https://doi.org/10.1016/j.jstrokecerebrovasdis.2015.11.035.CrossRefPubMedGoogle Scholar
- 17.Loubinoux I, Boulanouar K, Ranjeva JP, et al. Cerebral functional magnetic resonance imaging activation modulated by a single dose of the monoamine neurotransmission enhancers fluoxetine and fenozolone during hand sensorimotor tasks. J Cereb Blood Flow Metab. 1999;19(12):1365–75. https://doi.org/10.1097/00004647-199912000-00010.CrossRefPubMedGoogle Scholar
- 18.Loubinoux I, Pariente J, Boulanouar K, et al. A single dose of the serotonin neurotransmission agonist paroxetine enhances motor output: double-blind, placebo-controlled, fMRI study in healthy subjects. Neuroimage. 2002;15(1):26–36. https://doi.org/10.1006/nimg.2001.0957.CrossRefPubMedGoogle Scholar
- 24.Jorge RE, Acion L, Moser D, Adams HP Jr, Robinson RG. Escitalopram and enhancement of cognitive recovery following stroke. Arch Gen Psychiatry. 2010;67(2):187–96. https://doi.org/10.1001/archgenpsychiatry.2009.185.CrossRefPubMedPubMedCentralGoogle Scholar
- 35.Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med. 2003;163(1):59–64. https://doi.org/10.1001/archinte.163.1.59.CrossRefPubMedGoogle Scholar
- 37.Mortensen JK, Larsson H, Johnsen SP, Andersen G. Post stroke use of selective serotonin reuptake inhibitors and clinical outcome among patients with ischemic stroke: a nationwide propensity score-matched follow-up study. Stroke. 2013;44(2):420–6. https://doi.org/10.1161/STROKEAHA.112.674242.CrossRefPubMedGoogle Scholar
- 59.Mead G, Hackett ML, Lundstrom E, Murray V, Hankey GJ, Dennis M. The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: A study protocol for three multicentre randomised controlled trials. Trials. 2015. https://doi.org/10.1186/s13063-015-0864-1.CrossRefPubMedPubMedCentralGoogle Scholar
- 63.Gelernter J, Cubells JF, Kidd JR, Pakstis AJ, Kidd KK. Population studies of polymorphisms of the serotonin transporter protein gene. Am J Med Genet. 1999;88(1):61–6. https://doi.org/10.1002/(SICI)1096-8628(19990205)88:13.0.CO;2-K.CrossRefPubMedGoogle Scholar